MarketPR
A $820 million upfront payment sets the price of entry.
Jazz Pharmaceuticals has agreed to acquire San Diego-based Actio Biosciences for up to $1.3 billion, adding a potential first-in-class treatment for KCNT1-related epilepsy to a neuroscience portfolio that already houses Epidiolex.
The two companies expect the transaction to close in the fourth quarter of 2026.
Deal structure and the balance sheet The full figure carries conditionality: Actio collects $820 million at close, with the remaining $500 million tied to regulatory and sales milestones.
Keep reading